Celgene sells psoriasis pill to Amgen for $13.4b, on way to Bristol merger

Celgene sells psoriasis pill to Amgen for $13.4b, on way to Bristol merger

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

By ADAM FEUERSTEIN

RIC FRANCIS/AP

Amgen will buy the psoriasis pill Otezla from Celgene, which is selling it to remove an obstacle from its planned merger with Bristol-Myers Squibb.

READ MORE